C12N 2310/321
2'-o-r modification
Official title: 2'-O-R Modification
C12N2310/321 (2'-o-r modification) appears on 2,863 US grants and 5,315 published applications in this corpus.
Search patents in C12N- Granted patents
- 2,863
- Published applications
- 5,315
- Assignees
- 995
- Inventors
- 4,964
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 4 | 0 |
| 1994 | 2 | 0 |
| 1995 | 8 | 0 |
| 1996 | 25 | 0 |
| 1997 | 44 | 0 |
| 1998 | 42 | 0 |
| 1999 | 81 | 0 |
| 2000 | 101 | 0 |
| 2001 | 92 | 12 |
| 2002 | 91 | 51 |
| 2003 | 59 | 262 |
| 2004 | 36 | 277 |
| 2005 | 27 | 194 |
| 2006 | 25 | 103 |
| 2007 | 24 | 126 |
| 2008 | 24 | 81 |
| 2009 | 43 | 158 |
| 2010 | 82 | 145 |
| 2011 | 93 | 160 |
| 2012 | 104 | 162 |
| 2013 | 106 | 153 |
| 2014 | 125 | 154 |
| 2015 | 163 | 227 |
| 2016 | 136 | 225 |
| 2017 | 138 | 206 |
| 2018 | 135 | 202 |
| 2019 | 144 | 212 |
| 2020 | 139 | 232 |
| 2021 | 140 | 260 |
| 2022 | 140 | 275 |
| 2023 | 112 | 303 |
| 2024 | 149 | 391 |
| 2025 | 120 | 406 |
| 2026 | 108 | 338 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method for optimized RIG-I ligands6 Oct 2026US 12,751,965 B2
- Chemically modified oligonucleotides targeting bromodomain containing protein 4 (BRD4) for immunotherapy6 Oct 2026US 12,753,407 B2Phio Pharmaceuticals Corp.
- OPA1 antisense oligomers for treatment of conditions and diseases6 Oct 2026US 12,753,408 B2Stoke Therapeutics, Inc.
- Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof6 Oct 2026US 12,753,409 B2Hangzhou Tianlong Pharmaceutical Co., Ltd.
- Antisense oligonucleotides for the treatment of stargardt disease29 Sep 2026US 12,747,440 B2ProQR Therapeutics II B.V.
- Modified guide rnas8 Oct 2026US 2026/0308577 A1Genentech, Inc.
- Reducing intron retention8 Oct 2026US 2026/0308583 A1University of Southampton
- Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)8 Oct 2026US 2026/0308585 A1Alnylam Pharmaceuticals, Inc.
- Sugar Modified Oligonucleotides and Uses Thereof8 Oct 2026US 2026/0308587 A1Ionis Pharmaceuticals, Inc.
- Compositions and methods for regulating expression of atxn28 Oct 2026US 2026/0308591 A1Riboway Therapeutics, Inc.
Most cited
By later US patents
- Genetic inhibition by double-stranded RNA1,185US 6,506,559 B1Carnegie Institute of Washington · 2003
- Antisense oligonucleotide modulation of multidrug resistance-associated protein841US 5,801,154 AIsis Pharmaceuticals, Inc. · 1998
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Oligonucleotide therapeutic agent and method of making same726US 5,023,243 AMolecular Biosystems, Inc. · 1991
- Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved663US 5,403,711 AUniversity of Iowa Research Foundation · 1995